Evidence map›Paper›PMID 39028003›Full record

ArticleThe Journal of infectious diseases2025

Plasma Immune Biomarkers Predictive of Progression to Active Tuberculosis in Household Contacts of Patients With Tuberculosis.

Anuradha Rajamanickam, Evangeline Ann Daniel, Bindu Dasan, Kannan Thiruvengadam, Padmapriyadarsini Chandrasekaran, Sanjay Gaikwad, Sathyamurthi Pattabiraman, Brindha Bhanu, Amsaveni Sivaprakasam, Vandana Kulkarni and 7 more

Abstract read
In one paragraph

Article in The Journal of infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Anuradha RajamanickamNational Institute of Health-National Institute of Allergy and Infectious Diseases-International Center for Excellence in Research, Chennai, India.ORCID 0000-0002-8143-5502
Evangeline Ann DanielICMR-National Institute for Research in Tuberculosis, Indian Council of Medical Research, Chennai, India.
Bindu DasanNational Institute of Health-National Institute of Allergy and Infectious Diseases-International Center for Excellence in Research, Chennai, India.
Kannan ThiruvengadamICMR-National Institute for Research in Tuberculosis, Indian Council of Medical Research, Chennai, India.
Padmapriyadarsini ChandrasekaranICMR-National Institute for Research in Tuberculosis, Indian Council of Medical Research, Chennai, India.
Sanjay GaikwadDepartment of Pulmonary Medicine, Byramjee Jeejeebhoy Government Medical College and Sassoon General Hospitals, Pune, India.
Sathyamurthi PattabiramanICMR-National Institute for Research in Tuberculosis, Indian Council of Medical Research, Chennai, India.
Brindha BhanuICMR-National Institute for Research in Tuberculosis, Indian Council of Medical Research, Chennai, India.
Amsaveni SivaprakasamICMR-National Institute for Research in Tuberculosis, Indian Council of Medical Research, Chennai, India.
Vandana KulkarniByramjee Jeejeebhoy Government Medical College-Johns Hopkins Clinical Research Site, Pune, India.
Rajesh KaryakarteDepartment of Microbiology, Byramjee Jeejeebhoy Government Medical College and Sassoon General Hospitals, Pune, India.
Mandar ParadkarByramjee Jeejeebhoy Government Medical College-Johns Hopkins Clinical Research Site, Pune, India.
Shri Vijay Bala Yogendra ShivakumarJohns Hopkins Center for Infectious Diseases in India, Pune, India.
Vidya MaveByramjee Jeejeebhoy Government Medical College-Johns Hopkins Clinical Research Site, Pune, India.ORCID 0000-0001-8509-4517
Amita GuptaDivision of Infectious Diseases, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.ORCID 0000-0001-7036-2718
Luke Elizabeth HannaICMR-National Institute for Research in Tuberculosis, Indian Council of Medical Research, Chennai, India.
Subash BabuNational Institute of Health-National Institute of Allergy and Infectious Diseases-International Center for Excellence in Research, Chennai, India.

Funding

India International Center for Excellence in ResearchZIAAI001065 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI NUTMAN, THOMAS · 2009 to 2025
$19.0M
CRDF Global USB1-31149-XX-13Department of BiotechnologyGovernment of India'sIndian Council of Medical ResearchNational Institute of Allergy and Infectious DiseasesNHLBI NIH HHSNIH HHSOffice of AIDS Research(support to S. B.)
6 · The paper itself

Abstract

backgroundThe progression from Mycobacterium tuberculosis infection to active tuberculosis disease varies among individuals, and identifying biomarkers to predict progression is crucial for guiding interventions. In this study, we aimed to determine plasma immune biomarker profiles in healthy household contacts of index patients with pulmonary tuberculosis, who either progressed to tuberculosis or remained as nonprogressors.

methodsA cohort of household contacts of adults with pulmonary tuberculosis was enrolled, consisting of 15 contacts who progressed to tuberculosis disease and 15 nonprogressors. Plasma samples were collected at baseline, 4 months, and 12 months to identify predictive tuberculosis progression markers.

resultsOur findings revealed that individuals in the progressor group exhibited significantly decreased levels of interferon (IFN) γ, tumor necrosis factor α, interleukin 2, IL-1α, IL-1β, and 17A, and interleukin 1 receptor antagonist (IL-1Ra) at baseline, month 4, and month 12. In contrast, the progressor group displayed significantly elevated levels of IFN-α, IFN-β, interleukin 6 and 12, granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin 10 (IL-10) and 33 (IL-33), CCL2, CCL11, CXCL8, CXCL10, CX3CL1, vascular endothelial growth factor, granzyme B, and programmed death ligand -1 compared to the nonprogressor group at baseline, months 4 and 12. Receiver operating characteristic analysis (ROC) identified IFN-γ, GM-CSF, IL-1Ra, CCL2, and CXCL10 as the most promising predictive markers, with an area under the receiver operating characteristic curve of ≥90. Furthermore, combinatorial analysis demonstrated that GM-CSF, CXCL10, and IL-1Ra, when used in combination, exhibited high accuracy in predicting progression to active tuberculosis disease.

conclusionsOur study suggests that a specific set of plasma biomarkers, GM-CSF, CXCL10, and IL-1Ra, can effectively identify household contacts at significant risk of developing tuberculosis disease. These findings have important implications for early intervention and preventive strategies in tuberculosis-endemic regions.

Indexed as

BiomarkersCytokinesTuberculosisTuberculosis, PulmonaryAdultDisease ProgressionFamily CharacteristicsFemaleHumansMaleMiddle AgedMycobacterium tuberculosisYoung AdultBiomarkersCytokinesCytokines, chemokines and Growth Factorslatent tuberculosisplasma biomarkersprogressiontuberculosis

Identifiers

PMID39028003
PMCPMC11911786

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.